Activation of peroxisome proliferator-activated receptor gamma and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 3, 2003, Pages 475-482

  Argmann, C A ^a   Sawyez, C G ^a   McNeil, C J ^a   Hegele, R A ^a   Huff, M W ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Macrophages; Oxidized lipoproteins; PPAR

Indexed keywords

ABC TRANSPORTER; ALITRETINOIN; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ESTER; CIGLITAZONE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; FOAM CELL; GENE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ARTERIOSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; HUMANS; LIPOPROTEINS; MACROPHAGES; MEMBRANE TRANSPORT PROTEINS; MICE; OXIDATION-REDUCTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANSCRIPTION FACTORS;

EID: 0037343227     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000058860.62870.6E     Document Type: Article

References (38)

1. Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J Mol Med. 2002;80:271-281.
2. Fruchart J-C, Staels B, Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res. 2001;44:345-352.
3. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell. 1995;83:803-812.
4. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
5. Clark RB. The role of PPARs in inflammation and immunity. J Leukocyte Biol. 2002;71:388-400.
6. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
7. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocytelmacrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
8. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart J-C, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atheroslcerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
9. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
10. Marx J, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ. Differentiation-dependent peroxisomal proliferator-activated γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
11. Torra IP, Chinetti G, Duval C, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipid. 2001;12:245-254.
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazoldinedione is a high affinity ligand for peroxisome proliferator-activated receptors. J Biol Chem. 1995;270:12953-12956.
13. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-774.
14. Escher P, Whali W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res. 2000;448:121-138.
15. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med. 2001;7:41-47.
16. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
17. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPARγ. J Lipid Res. 2000;41:688-696.
18. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998;82:229-240.
19. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:629-631.
20. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-371.
21. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki G, Yahagi N, Iizuka Y, Shionoiri G, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:372-377.
22. Chawla A, Boisvert WA, Lee C, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
23. Spiegelman BM. PPARγ in monocytes: less pain, any gain? Cell. 1998;93:153-155.
24. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart J-C, Clavey V, Staels B. PPARα and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
25. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1 and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22:2607-2619.
26. Orsó E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W, Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani M, Rothe G, Lackner KJ, Chimini G, Schmitz G. Transport of lipids from golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat Genet. 2000;24:192-196.
27. Lawn RM, Wade DP, Garvin MR, Wang X, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-R31.
28. Yancey PG, Jerome WG. Lysosomal sequestration of free and esterified cholesterol from oxidized low density lipoprotein in macrophages of different species. J Lipid Res. 1998;39:1349-1361.
29. Lougheed M, Ming Lum, C, Ling W, Suzuki H, Kodama T, Steinbrecher UP. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem. 1997;272:12938-12944.
30. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW. Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. 2001;21:2011-2018.
31. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J Biol Chem. 2000;275:1873-1877.
32. Song C, Hiipakka RA, Liao S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids. 2001;66:473-479.
33. Claudel T, Leibowitz MD, Fiévet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro J, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction in atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A. 2001;98:2610-2615.
34. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002: in press.
35. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289:1524-1529.
36. Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001;42:1513-1520.
37. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent activation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-28245.
38. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235-1242.